Oral News and Research

RSS

FDA approves Amneal's generic Furadantin

Amneal Pharmaceuticals, LLC is pleased to announce that it has received U.S. FDA approval to manufacture Nitrofurantoin Oral Suspension in the 25 mg/5 ml strength effective May 13, 2011. Amneal's generic, the first on the market, is an AA-rated, therapeutically equivalent alternative to Furadantin.

23 May 2011

Pieris' PRS-080 preclinical data in anemia presented at International BioIron Society Meeting

Pieris AG announced today preclinical in vitro and in vivo data for its PRS-080 Anticalin antagonist program targeting hepcidin, a small peptide which plays a pivotal role in the regulation of iron levels in the blood.

23 May 2011

New data from ProSavin Phase I/II trial in Parkinson's presented at ASGCT annual meeting

Oxford BioMedica, a leading gene therapy company, announces that new data from the on-going Phase I/II trial of ProSavin for the treatment of Parkinson's disease were presented at the American Society of Gene & Cell Therapy 14th Annual Meeting held in Seattle, USA by Professor Stephane Palfi, Principal Investigator at the Henri Mondor Hospital in Paris, on Saturday 21 May 2011.

23 May 2011

Sosei to introduce NorLevo oral emergency contraceptive in Japan

Sosei Group Corporation, the biopharmaceutical company, today announced that Sosei Co., Ltd., its wholly owned Japanese subsidiary, will launch its emergency contraceptive pill, NorLevo(R) TABLETS 0.75mg, tomorrow 24 May, through the distribution network of its commercialization partner, ASKA Pharmaceutical Co., Ltd.

23 May 2011

Lilly Phase I multiple myeloma study affirms potential of LY2127399-bortezomib combination

Eli Lilly and Company announced Phase I data on LY2127399, a human monoclonal antibody that neutralizes B-cell activating factor (BAFF), for use in combination with bortezomib in patients with previously-treated multiple myeloma.

21 May 2011

American Dental Association launches new ADA Seal of Acceptance Web area

The American Dental Association (ADA) launched its new ADA Seal of Acceptance Web area this week.

21 May 2011

Stony Brook University CFB establishes Biotechnology Commercialization Fund

The Center for Biotechnology (CFB) at Stony Brook University has established the Biotechnology Commercialization Fund to accelerate the development of promising biomedical technologies emerging from Stony Brook University.

21 May 2011

Bristol-Myers Squibb to present abstracts on oncology compounds at ASCO 2011 Annual Meeting

Bristol-Myers Squibb Company, a leading global BioPharma company in oncology, today announced that more than 95 scientific abstracts on its approved and investigational oncology compounds will be featured at the 47th Annual Meeting of the American Society of Clinical Oncology in Chicago from June 3-7.

21 May 2011

Inorganic nitrate reduces rate of heart dysfunction caused by doxorubicin

Virginia Commonwealth University researchers have found that nutrient supplementation, like the kind that is found in leafy greens, spinach and lettuce, may reduce the damage to the heart caused by a powerful anti-cancer drug.

20 May 2011

EMA CHMP recommends conditional marketing authorization of FAMPYRA

The Committee for Medicinal Products for Human Use of the European Medicine Agency has recommended conditional marketing authorization of FAMPYRA (prolonged-release fampridine 10 mg tablets) for the improvement of walking in adult patients with multiple sclerosis with walking disability.

20 May 2011

Jennerex presents positive preliminary data from JX-594 Phase 2 trial for advanced liver cancer

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the design, development and commercialization of first-in-class targeted oncolytic products for cancer, today presented preliminary data from a randomized dose-ranging Phase 2 trial of JX-594 in patients with advanced liver cancer showing a benefit in overall survival for the high dose group.

20 May 2011

Indian wild plants offer hope against resistant infections

Cancer treatments often have the side effect of impairing the patient's immune system. This can result in life-threatening secondary infections from bacteria and fungi, especially since bacteria, like Staphylococcus aureus, are becoming multi-drug resistant.

20 May 2011

Cholesterol drug may help treat mitochondrial diseases

A human drug that both prevents and cures kidney failure in mice sheds light on disabling human mitochondrial disorders, and may represent a potential treatment in people with such illnesses.

20 May 2011

RTOG reports on largest trial for newly diagnosed glioblastoma

RTOG reports on the largest trial to-date for patients with newly diagnosed glioblastoma demonstrating the importance and feasibility of prospective molecular analysis of tumor tissue although finding that patients received no additional benefit from dose-intensive temozolomide as compared to standard adjuvant temozolomide after combined temozolomide and radiotherapy.

20 May 2011

Bayer, Onyx to present Nexavar-chemotherapy combination Phase 2b trial data in breast cancer at ASCO 2011

Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. today announced results from a Phase 2b trial evaluating Nexavar® (sorafenib) tablets in patients with locally advanced or metastatic breast cancer previously treated with a bevacizumab-containing regimen, which showed that Nexavar was associated with statistically significant improvements in progression-free survival and time-to-progression.

20 May 2011

Study: Costs get in way of cancer patients refilling their prescriptions

About 10 percent of cancer patients aren't taking the oral medicines they need either because of the cost or they feel they are already taking too many other drugs, according to a study released by health-care consulting company Avalere Health late Wednesday.

20 May 2011

Lilly's cixutumumab Phase II study results in five subtypes of sarcoma to be presented at 47th ASCO

Eli Lilly and Company announced data from its Phase II study with cixutumumab in five subtypes of sarcoma, a cancer that develops from connective tissues in the body.

20 May 2011

ViroPharma commences VP 20621 Phase 2 study for prevention of recurrent Clostridium difficile infection

ViroPharma Incorporated today announced initiation of a Phase 2 dose-ranging clinical study to evaluate the safety, tolerability, and efficacy of VP 20621 for prevention of recurrence of Clostridium difficile infection (CDI) in adults previously treated for CDI.

20 May 2011

CEL-SCI initiates global Multikine Phase III trial for head and neck cancer in Russia

CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine®, the Company's flagship immunotherapy, in Russia at the State Budgetary Healthcare Institution of Sverdlovsk Region - Sverdlovsk Regional Oncology Center in Ekaterinburg, Russia.

20 May 2011

CSL-Behring recombinant factor research presented

Advances that CSL Behring is making in developing innovative new technologies to meet the unmet therapeutic needs of patients with hemophilia A and B will be the topic of an oral presentation at an international medical congress on May 22, 2011. CSL Behring is a global biotherapeutics company specializing in plasma-derived and recombinant therapies and is a subsidiary of CSL Limited (ASX:CSL).

19 May 2011

Oral News and Research

FDA approves Amneal's generic Furadantin

Pieris' PRS-080 preclinical data in anemia presented at International BioIron Society Meeting

New data from ProSavin Phase I/II trial in Parkinson's presented at ASGCT annual meeting

Sosei to introduce NorLevo oral emergency contraceptive in Japan

Lilly Phase I multiple myeloma study affirms potential of LY2127399-bortezomib combination

American Dental Association launches new ADA Seal of Acceptance Web area

Stony Brook University CFB establishes Biotechnology Commercialization Fund

Bristol-Myers Squibb to present abstracts on oncology compounds at ASCO 2011 Annual Meeting

Inorganic nitrate reduces rate of heart dysfunction caused by doxorubicin

EMA CHMP recommends conditional marketing authorization of FAMPYRA

Jennerex presents positive preliminary data from JX-594 Phase 2 trial for advanced liver cancer

Indian wild plants offer hope against resistant infections

Cholesterol drug may help treat mitochondrial diseases

RTOG reports on largest trial for newly diagnosed glioblastoma

Bayer, Onyx to present Nexavar-chemotherapy combination Phase 2b trial data in breast cancer at ASCO 2011

Study: Costs get in way of cancer patients refilling their prescriptions

Lilly's cixutumumab Phase II study results in five subtypes of sarcoma to be presented at 47th ASCO

ViroPharma commences VP 20621 Phase 2 study for prevention of recurrent Clostridium difficile infection

CEL-SCI initiates global Multikine Phase III trial for head and neck cancer in Russia

CSL-Behring recombinant factor research presented

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News